Merus NV: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Merus NV Unternehmen

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Merus NV Informationen



BörsenkürzelMRUS

Name des UnternehmensMerus NV

IPO-datumMay 19, 2016

CEOLundberg (Sven Ante)

Anzahl der mitarbeiter260

WertpapierartOrdinary Share

GeschäftsjahresendeMay 19

AddresseYalelaan 62

StadtUTRECHT

BörseNASDAQ OMX - NASDAQ BASIC

LandNetherlands

Postleitzahl3584 CM

Telefon310302538800

Websitehttps://merus.nl/

BörsenkürzelMRUS

IPO-datumMay 19, 2016

CEOLundberg (Sven Ante)

Führungskräfte von Merus NV



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Sven Ante (Bill) Lundberg, M.D.

President, Chief Executive Officer, Executive Director

168.44K

-30297.00%

Mr. Mark T. Iwicki

Non-Executive Independent Director

--

Mr. Peter B. Silverman, J.D.

Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal

--

Dr. Anand Mehra, M.D.

Non-Executive Independent Chairman of the Board

--

Mr. Gregory D. (Greg) Perry

Chief Financial Officer

--

Mr. Leonard (Len) Kanavy

Non-Executive Independent Director

--

Mr. Paolo Pucci

Non-Executive Independent Director

--

Dr. Victor Sandor, M.D.

Non-Executive Independent Director

--

Ms. Sherri Spear

Investor Relations and Corporate Communications

--

Dr. Maxine Gowen, Ph.D.

Non-Executive Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Sven Ante (Bill) Lundberg, M.D.

President, Chief Executive Officer, Executive Director

168.44K

-30297.00%

Mr. Mark T. Iwicki

Non-Executive Independent Director

--

Mr. Peter B. Silverman, J.D.

Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal

--

Dr. Anand Mehra, M.D.

Non-Executive Independent Chairman of the Board

--

Mr. Gregory D. (Greg) Perry

Chief Financial Officer

--

Mr. Leonard (Len) Kanavy

Non-Executive Independent Director

--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sat, Jan 3

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Paradigm BioCapital Advisors LP

5.77%

Avoro Capital Advisors LLC

4.67%

Commodore Capital LP

4.65%

Deerfield Management Company, L.P.

4.02%

HBK Investments, L.P.

3.76%

Andere

77.14%

Aktionäre

Anteil

Paradigm BioCapital Advisors LP

5.77%

Avoro Capital Advisors LLC

4.67%

Commodore Capital LP

4.65%

Deerfield Management Company, L.P.

4.02%

HBK Investments, L.P.

3.76%

Andere

77.14%

Aktionärstypen

Aktionäre

Anteil

Hedge Fund

39.38%

Investment Advisor/Hedge Fund

27.56%

Investment Advisor

13.49%

Research Firm

2.54%

Corporation

1.93%

Private Equity

1.78%

Venture Capital

1.47%

Pension Fund

0.56%

Bank and Trust

0.49%

Andere

10.81%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

498

69.89M

92.15%

-15.18M

2025Q3

434

77.32M

101.98%

-5.60M

2025Q2

411

75.46M

99.77%

-10.50M

2025Q1

420

74.82M

101.12%

-10.15M

2024Q4

398

74.69M

108.18%

-7.45M

2024Q3

373

72.99M

107.03%

-6.71M

2024Q2

355

69.91M

103.77%

+7.77M

2024Q1

315

57.35M

97.63%

-5.32M

2023Q4

282

57.36M

99.41%

-5.55M

2023Q3

268

57.60M

100.50%

+2.76M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Paradigm BioCapital Advisors LP

4.37M

5.77%

+91.82K

+2.14%

Sep 30, 2025

Avoro Capital Advisors LLC

3.54M

4.67%

+386.94K

+12.26%

Sep 30, 2025

Commodore Capital LP

3.52M

4.65%

--

Sep 30, 2025

Deerfield Management Company, L.P.

3.05M

4.02%

-337.71K

-9.98%

Sep 30, 2025

HBK Investments, L.P.

2.85M

3.76%

+2.85M

--

Sep 30, 2025

Westfield Capital Management Company, L.P.

2.13M

2.81%

+90.10K

+4.41%

Sep 30, 2025

RTW Investments L.P.

2.03M

2.67%

-1.98M

-49.38%

Sep 30, 2025

Fidelity Management & Research Company LLC

1.94M

2.55%

-4.28M

-68.87%

Sep 30, 2025

Woodline Partners LP

1.67M

2.21%

+131.27K

+8.51%

Sep 30, 2025

Glazer Capital, LLC

1.62M

2.13%

+1.62M

--

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Tue, Dec 2

Name

Anteil

AltShares Merger Arbitrage ETF

3.3%

NYLI Merger Arbitrage ETF

3.1%

ALPS Medical Breakthroughs ETF

2.89%

Goldman Sachs Hedge Industry VIP ETF

2.75%

ProShares Merger ETF

2.74%

First Trust IPOX Europe Equity Opportunities ETF

2.61%

Tema Oncology ETF

2.61%

Invesco Dorsey Wright Healthcare Momentum ETF

1.4%

Harbor Health Care ETF

1.29%

AltShares Event-Driven ETF

1.23%

AltShares Merger Arbitrage ETF

Anteil3.3%

NYLI Merger Arbitrage ETF

Anteil3.1%

ALPS Medical Breakthroughs ETF

Anteil2.89%

Goldman Sachs Hedge Industry VIP ETF

Anteil2.75%

ProShares Merger ETF

Anteil2.74%

First Trust IPOX Europe Equity Opportunities ETF

Anteil2.61%

Tema Oncology ETF

Anteil2.61%

Invesco Dorsey Wright Healthcare Momentum ETF

Anteil1.4%

Harbor Health Care ETF

Anteil1.29%

AltShares Event-Driven ETF

Anteil1.23%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten